Misinformation in the medical literature: What role do error and fraud play?: Table 1
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Media attention to retracted research suggests that a substantial number of papers are corrupted by misinformation. In reality, every paper contains misinformation; at issue is whether the balance of correct versus incorrect information is acceptable. This paper postulates that analysis of retracted research papers can provide insight into medical misinformation, although retracted papers are not a random sample of incorrect papers. Error is the most common reason for retraction and error may be the principal cause of misinformation as well. Still, one-quarter of retracted papers are fraudulent, and misinformation may also arise through fraud. This paper hypothesises that error and fraud are the main sources of misinformation and that error is more common than fraud. Retraction removes misinformation from the literature; bias is non-retracted misinformation. Bias arises when scientific impropriety results in false research findings. Impropriety can involve experimental design, data collection, data analysis, or data presentation. Yet impropriety also arises through earnest error or statistical naiveté; not all bias is fraud. Several measures are proposed to minimise misinformation in the medical literature, including: greater detail in the clinical trial registry, with rigorous definition of inclusion and exclusion criteria and primary endpoints; clear statistical criteria for every aspect of clinical trials, especially sample size; responsibility for data integrity that accrues to all named authors; increased transparency as to how the costs of research were paid; and greater clarity as to the reasons for retraction. Misinformation can arise without malicious intent; authors of incorrect papers are owed a presumption of incompetence, not malice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 2×
“If a company funds research on a specific medication, then published results tend to favour that product.(8) These findings suggest two plausible interpretations: either the publication is misleading (eg, highlight the good news, bury the bad) or drug makers are clever enough to predict which medications are likely to…”
BackgroundResultRosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036 · cited 2×
“AURORA enrolled 2776 patients with end-stage renal disease on maintenance haemodialysis, and patients were randomly assigned to placebo or rosuvastatin.(11) After 3.”
BackgroundMethodChan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845 · cited 1×
“Selective outcome reporting is apparently common in RCT. Among 122 papers evaluated, which reported 3736 outcomes from 102 clinical trials, 50% of efficacy outcomes and 65% of harm outcomes per trial were incompletely reported.”
BackgroundBoutron, I. (2010) · JAMA · doi:10.1001/jama.2010.651 · Cited by 842 · cited 3×
“’ ‘Spin’ can involve arguments that seek to minimise the impact of negative information; among 72 published RCT in which every primary outcome was found to be statistically non-significant, several strategies were used to argue that treatment was still beneficial.(24) For example, attention was directed to significant…”
BackgroundResultInfluentialReporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Ray, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446 · cited 1×
“There is also little evidence that all-cause mortality is reduced by statins; a meta-analysis of mortality in 65 229 patients concluded that statins are not associated with significant survival benefit.”
BackgroundRetractions in the scientific literature: is the incidence of research fraud increasing?
Steen, R. G. (2011) · Journal of Medical Ethics · doi:10.1136/jme.2010.040923 · Cited by 405 · cited 2×
“The number of papers that are retracted yearly for fraud has increased sharply over the past decade, which may reflect either a real increase in the incidence of fraud or a greater effort on the part of journals to police the literature.(3) Papers retracted for fraud (fabrication or falsification) may represent a calc…”
BackgroundSelf-citationOutcome Reporting Among Drug Trials Registered in ClinicalTrials.gov
Bourgeois, F. T., Murthy, S., & Mandl, K. D. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00006 · Cited by 332 · cited 2×
“Logistic difficulties associated with large or complex industry trials may explain why publication is often slower following completion.(22) Finally, legal considerations also enforce caution; academic scientists who err in a clinical trial are largely immune from prosecution, but a company that makes an error may los…”
BackgroundRetractions in the scientific literature: do authors deliberately commit research fraud?
Steen, R. G. (2011) · Journal of Medical Ethics · doi:10.1136/jme.2010.038125 · Cited by 217
Self-citationEthical issues in stopping randomized trials early because of apparent benefit.
Mueller, P. S., Montori, V. M., Bassler, D., Koenig, B. A., & Guyatt, G. H. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00009 · Cited by 202 · cited 1×
“There are ethical problems associated with early stopping; truncated trials tend to overestimate treatment efficacy, and inflated estimates of efficacy put patients at risk.(25) Responsibilities for data integrity must be clearly articulated.”
Background
Cited by
Retracted Science and the Retraction Index
Fang, F. C., & Casadevall, A. (2011) · Infection and Immunity · doi:10.1128/iai.05661-11 · Cited by 405
RetractedThe visibility of scientific misconduct: A review of the literature on retracted journal articles
Hesselmann, F., Graf, V., Schmidt, M., & Reinhart, M. (2017) · Current Sociology · doi:10.1177/0011392116663807 · Cited by 153
“It is unanimously acknowledged that retraction rates have been rising steadily since the 1970s with further acceleration after 2000 (Cokol et al., 2008; Fanelli, 2013; Fang et al., 2012; Gasparyan et al., 2014; Grieneisen and Zhang, 2012; He, 2013; Redman et al., 2008; Steen, 2011a; Wager and Williams, 2011).”
BackgroundResultInfluentialVisibility of retractions: a cross-sectional one-year study
Decullier, E., Huot, L., Samson, G., & Maisonneuve, H. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-238 · Cited by 69
“misinformation without intent, can also diminish the quality of scientific evidence [5].”
BackgroundMethodByrne, J. A., & Labbé, C. (2017) · Scientometrics · doi:10.1007/s11192-016-2209-6 · Cited by 50
“This is supported by statistical analyses of journal impact factors of retracted articles due to suspected or admitted fraud versus the journal impact factors of articles retracted due to error (Fang et al. 2012; Steen 2011a).”
BackgroundMethodAn analysis of the validity of retraction annotation in pubmed and the web of science
Schmidt, M. (2018) · Journal of the Association for Information Science and Technology · doi:10.1002/asi.23913 · Cited by 47
Metadata
- Authors
- Steen, R. G.
- Venue
- Journal of Medical Ethics
- Publisher
- BMJ
- Published
- 2011-02-22
- Volume
- 37
- Issue
- 8
- Pages
- 498-503
- ISSN
- 0306-6800 (ISSN-L)
- 1473-4257
- OpenAlex
- W2148947157
- Cited by
- 46
- References
- 10
- FWCI
- 15.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Misinformation in the medical literature: What role do error and fraud play?: Table 1. https://app.cochat.ai/papers/10.1136/jme.2010.041830
- The paper
- Steen, R. G. (2011). Misinformation in the medical literature: What role do error and fraud play?: Table 1. Journal of Medical Ethics. https://doi.org/10.1136/jme.2010.041830
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.